Literature DB >> 16179940

Targeted induction of apoptosis by chimeric granzyme B fusion proteins carrying antibody and growth factor domains for cell recognition.

B Dälken1, U Giesübel, S K Knauer, W S Wels.   

Abstract

The serine protease granzyme B (GrB) of cytotoxic lymphocytes efficiently induces apoptosis by direct activation of caspases and cleavage of central caspase substrates. We employed human GrB as an effector function in chimeric fusion proteins that also contain the EGFR ligand TGFalpha or an ErbB2-specific single-chain antibody fragment (scFv) for selective targeting to tumor cells. GrB-TGFalpha (GrB-T) and GrB-scFv(FRP5) (GrB-5) molecules expressed in the yeast Pichia pastoris were bifunctional, cleaving synthetic and natural GrB substrates, and binding specifically to cells expressing EGFR or ErbB2 target receptors. Upon cell binding the chimeric molecules were internalized into intracellular vesicles, but could be released into the cytosol by the endosomolytic reagent chloroquine. Treatment with picomolar to nanomolar concentrations of GrB-5 and GrB-T resulted in selective and rapid tumor cell killing, accompanied by clear signs of apoptosis such as chromatin condensation, membrane blebbing, formation of apoptotic bodies and activation of endogenous initiator and effector caspases.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16179940     DOI: 10.1038/sj.cdd.4401773

Source DB:  PubMed          Journal:  Cell Death Differ        ISSN: 1350-9047            Impact factor:   15.828


  18 in total

1.  Synergistic effect of granzyme B-azurin fusion protein on breast cancer cells.

Authors:  Nafiseh Paydarnia; Shahryar Khoshtinat Nikkhoi; Azita Fakhravar; Mohsen Mehdiabdol; Hedieh Heydarzadeh; Saeed Ranjbar
Journal:  Mol Biol Rep       Date:  2019-04-01       Impact factor: 2.316

2.  Cell binding, internalization and cytotoxic activity of human granzyme B expressed in the yeast Pichia pastoris.

Authors:  Ulrike Giesübel; Benjamin Dälken; Hayat Mahmud; Winfried S Wels
Journal:  Biochem J       Date:  2006-03-15       Impact factor: 3.857

3.  The functionalized human serine protease granzyme B/VEGF₁₂₁ targets tumor vasculature and ablates tumor growth.

Authors:  Khalid A Mohamedali; Yu Cao; Lawrence H Cheung; Walter N Hittelman; Michael G Rosenblum
Journal:  Mol Cancer Ther       Date:  2013-07-15       Impact factor: 6.261

4.  Modularly Constructed Synthetic Granzyme B Molecule Enables Interrogation of Intracellular Proteases for Targeted Cytotoxicity.

Authors:  Patrick Ho; Christopher Ede; Yvonne Y Chen
Journal:  ACS Synth Biol       Date:  2017-05-22       Impact factor: 5.110

5.  Construction and characterization of novel, completely human serine protease therapeutics targeting Her2/neu.

Authors:  Yu Cao; Khalid A Mohamedali; John W Marks; Lawrence H Cheung; Walter N Hittelman; Michael G Rosenblum
Journal:  Mol Cancer Ther       Date:  2013-03-14       Impact factor: 6.261

6.  Granzyme B delivery via perforin is restricted by size, but not by heparan sulfate-dependent endocytosis.

Authors:  Florian C Kurschus; Edward Fellows; Elisabeth Stegmann; Dieter E Jenne
Journal:  Proc Natl Acad Sci U S A       Date:  2008-09-04       Impact factor: 11.205

7.  Maltose-binding protein enhances secretion of recombinant human granzyme B accompanied by in vivo processing of a precursor MBP fusion protein.

Authors:  Benjamin Dälken; Robert A Jabulowsky; Pranav Oberoi; Itai Benhar; Winfried S Wels
Journal:  PLoS One       Date:  2010-12-22       Impact factor: 3.240

Review 8.  Targeted toxins in brain tumor therapy.

Authors:  Yan Michael Li; Walter A Hall
Journal:  Toxins (Basel)       Date:  2010-11-01       Impact factor: 5.075

Review 9.  Natural and Designed Toxins for Precise Therapy: Modern Approaches in Experimental Oncology.

Authors:  Olga Shilova; Elena Shramova; Galina Proshkina; Sergey Deyev
Journal:  Int J Mol Sci       Date:  2021-05-07       Impact factor: 5.923

10.  EGFR-targeted granzyme B expressed in NK cells enhances natural cytotoxicity and mediates specific killing of tumor cells.

Authors:  Pranav Oberoi; Robert A Jabulowsky; Hayat Bähr-Mahmud; Winfried S Wels
Journal:  PLoS One       Date:  2013-04-03       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.